Dendritic Nanotechnologies' Priostar Family of Dendrimers Receives 'Technology Innovation of the Year' Award

Nov 09, 2005, 00:00 ET from Dendritic Nanotechnologies Inc.

    MOUNT PLEASANT, Mich., Nov. 9 /PRNewswire/ -- Dendritic Nanotechnologies
 Inc. (DNT), a company focused on the discovery, development, and
 commercialization of dendrimer technologies to create a new generation of
 innovative products for the identification and treatment of human diseases,
 has been awarded the "Advanced Medical Applications Technology Innovation of
 the Year" Award by a leading global growth consulting company. The Award was
 bestowed on DNT by Frost & Sullivan for its work in developing and
 commercializing the Priostar(TM) family of dendrimers.
     Frost & Sullivan selected DNT from a field of several dozen nanotech
 companies. After a selection process that included primary participant
 interviews and extensive primary and secondary research, Frost & Sullivan
 concluded that DNT's dendrimer-based nanostructures "represent a potent
 delivery platform for a vast array of diagnostics and therapeutics and could
 be employed to manufacture a variety of biotechnology and pharmaceutical
     Of particular importance during the evaluation process was the precise
 control over size, composition, surface functionality and interior space
 offered by the Priostar family of dendrimers. Precise control of their
 physical characteristics means that Priostar dendrimers can be tailored to a
 wide array of markets, including medical and health, food and agriculture,
 energy and electronics, environmental and industrial safety, personal and
 household, and chemicals and manufacturing.
     Frost & Sullivan also noted that:  "While nanotechnology in general has
 promised great advances, there are relatively few tangible products with clear
 and present applications. Moreover, many of these products cannot be
 cost-effectively produced in large enough volumes. DNT's dendritic
 nanostructures appear to be an exception. These dendritic polymers can serve
 as effective delivery vehicles in vitro and in vivo due to their specific,
 precise and predictable architecture."
     "DNT's Priostar dendrimers, as nanoscale building blocks, radically change
 the current economics of nanotechnology and we are pleased to see them
 validated by a prestigious growth consulting company such as Frost &
 Sullivan," said Robert Berry, DNT's chief executive officer. "Priostar has
 established a new price point for an essential technology, placing it within
 reach of new applications and uses."
     About Frost & Sullivan
     Frost & Sullivan, a global growth consulting company, has been partnering
 with clients to support the development of innovative strategies for more than
 40 years. The company's industry expertise integrates growth consulting,
 growth partnership services, and corporate management training to identify and
 develop opportunities. Frost & Sullivan serves an extensive clientele that
 includes Global 1000 companies, emerging companies, and the investment
 community by providing comprehensive industry coverage that reflects a unique
 global perspective and combines ongoing analysis of markets, technologies,
 econometrics, and demographics. For more information, visit
     About DNT
     Dendritic Nanotechnologies Inc. (DNT) is focused on the discovery,
 development, and commercialization of dendrimer technologies to create a new
 generation of innovative products for the identification and treatment of
 human diseases. DNT's proprietary dendrimer platform serves as a targeted
 diagnostic and therapeutic delivery system for a wide variety of drugs to
 cancer cells and other diseases. Improved efficacy, enhanced solubility, and
 lower toxicity have been demonstrated for many existing drugs. DNT is
 committed to producing commercially viable dendrimers that can be manufactured
 in large quantities, and to driving down manufacturing complexity and costs.
 The company has a patent pending on its Priostar(TM) family of dendrimers, a
 novel dendrimer family that breaks through previous cost and manufacturing
     DNT's technology development is directed by Donald A. Tomalia, Ph.D.,
 president and chief technical officer. Dr. Tomalia is the inventor of
 dendrimers and has led numerous commercial developments during a 25-year
 management and senior scientist career with The Dow Chemical Company. See
     Starpharma (ASX: SPL) is an equity holder in DNT and is focused on the
 development and application of dendrimer nanotechnologies as drugs against
 major diseases. Starpharma's lead dendrimer product, VivaGel(TM) is currently
 in U.S. FDA Phase II human clinical trials. VivaGel is a topical microbicide
 gel product that has been developed for women as a preventative against the
 sexual transmission of HIV.
     NOTE:  STARBURST and Priostar are trademarks of Dendritic Nanotechnologies
 Inc. All other trademarks mentioned herein are held by their respective owners.

SOURCE Dendritic Nanotechnologies Inc.